Sleep Apnea: India’s Silent Epidemic – Underdiagnosis, Low CPAP Adoption, and Critical Awareness Gaps in Respiratory Health

Until recently, OSA prevalence in India was estimated at 5–11 %. A 2023 systematic review and meta-analysis of eight studies (n=11,009 adults) reported a pooled prevalence of 11% for any OSA (AHI ≥5 events/h) and 5% for moderate-to-severe OSA (AHI ≥15), translating to approximately 104 million working-age Indians affected, of whom 47 million have moderate-to-severe OSA. Urban rates range from 9–20 %, rising to 30–40 % in high-risk groups such as those with diabetes or metabolic syndrome.
A landmark 2025 study from the BLESS cohort in central India upended these figures. Using Level-1 PSG (the gold standard) on 958 apparently healthy adults (median age 40 years, median BMI 23.5 kg/m²), researchers documented an astonishing 75.9 % prevalence of at least mild OSA and 30.5 % (95 % CI 28–34 %) for moderate-to-severe disease; severe OSA (AHI ≥30) stood at 10.1 % (95 % CI 8.3–12 %). Even more striking, the upper quartile of AHI (≥17) was independently associated with diabetes (OR 2.14), hypertension (OR 1.98), and metabolic syndrome (OR 2.36). These associations held after adjustment, underscoring OSA’s role in India’s NCD crisis. Notably, the cohort’s near-normal BMI highlights that craniofacial anatomy, genetic predisposition, and urban lifestyle factors drive OSA in non-obese Indians – a profile often missed by Western-centric screening tools.
Extrapolating these recent PSG-based findings to the national level, India likely harbours well over 100 million adults with clinically significant OSA – more than 10 crore, as noted in a 2026 commentary. This burden intersects dangerously with India’s diabetes prevalence (>100 million) and hypertension epidemic, creating a vicious cycle of nocturnal hypoxemia, sympathetic overdrive, and endothelial dysfunction.

Despite the scale, underdiagnosis remains the norm. Global data suggest 82–93 % of moderate-to-severe OSA cases go undetected; in India, the figure exceeds 85 % among working-age adults. Only about 2 lakh sleep studies are performed annually across roughly 250 dedicated sleep-lab beds nationwide – a fraction of the need. Sleep medicine infrastructure is concentrated in metropolitan centres; in tier-2 and rural India, there is almost none. Fewer than 500 trained sleep specialists serve 1.4 billion people.
Conventional screening questionnaires (STOP-BANG, Berlin, NOSAS) perform poorly in Indian populations, where craniofacial risk factors predominate over obesity. Primary-care physicians and even many specialists rarely suspect OSA in non-obese snorers or daytime-fatigued patients. The result: millions suffer unexplained hypertension, resistant diabetes, stroke, road-traffic accidents, and cognitive decline while their respiratory disorder remains untreated. A 2026 Lung India commentary aptly asks, “Sleep testing in India: Are we missing the opportunity?” The answer is unequivocally yes.

Public awareness of OSA is dismally low. National surveys show most Indians attribute poor sleep to stress, heat, or screens, rarely recognising snoring-plus-daytime-somnolence as a treatable respiratory disorder. Even among healthcare professionals, knowledge gaps persist; many cardiologists and diabetologists still do not routinely screen high-risk patients. The 2015 Indian consensus guidelines noted that “awareness among the lay public and even among primary care physicians is dismally low.” Little has changed in the subsequent decade.
Wearables (Apple Watch, Fitbit, Oura) are raising general sleep awareness, and the 2024–2025 FDA clearances for OSA risk detection may accelerate screening. Yet without structured education, these tools risk generating anxiety rather than action. Workplace and driver-screening programmes remain virtually absent, despite OSA’s proven link to road accidents.

India stands at a turning point. The 2026 Lung India commentary calls for national practice standards, accreditation of sleep physicians and technologists, and reimbursement reform to cover validated home sleep apnoea testing (HSAT) and Level-2/3 devices. Collaboration with IITs and start-ups can drive the development of indigenous, affordable CPAP and AI-assisted diagnostics tailored to Indian craniofacial phenotypes
Policy recommendations include:

• Integrating OSA screening into national NCD programmes (diabetes, hypertension, CVD).
• Subsidised CPAP for below-poverty-line and government employees.
• Mandatory training modules for primary-care doctors and specialists.
• Public campaigns tied to World Sleep Day linking “good sleep” to heart and metabolic health.
• Large-scale longitudinal studies to quantify the economic burden of undiagnosed OSA (absenteeism, productivity loss, healthcare costs).